Exagen Inc XGN.OQ XGN.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Vista California-based company is expected to report a 35.1% increase in revenue to $16.895 million from $12.51 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Exagen Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Exagen Inc is $12.00, about 2% above its last closing price of $11.76
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.15 | -0.14 | -0.18 | Missed | -27.2 |
Mar. 31 2025 | -0.20 | -0.20 | -0.20 | Met | 0.8 |
Dec. 31 2024 | -0.26 | -0.26 | -0.20 | Beat | 23.1 |
Sep. 30 2024 | -0.29 | -0.29 | -0.28 | Beat | 3.4 |
Jun. 30 2024 | -0.34 | -0.34 | -0.16 | Beat | 53.6 |
Mar. 31 2024 | -0.36 | -0.36 | -0.19 | Beat | 47.5 |
Dec. 31 2023 | -0.40 | -0.43 | -0.31 | Beat | 28.5 |
Sep. 30 2023 | -0.46 | -0.47 | -0.31 | Beat | 34 |
This summary was machine generated October 31 at 14:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments